News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Eli Lilly and Company, Merck KGaA Erbitux Fails to Stop Colon Cancer Before It Spreads
June 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Eli Lilly & Co. and Merck KGaA’s Erbitux, approved for advanced colon cancer, failed to slow tumors in a study designed to expand the medicine’s use to patients whose disease is in an earlier stage.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Eli Lilly and Company
MORE ON THIS TOPIC
Alzheimer’s disease
INmune Crashes After Missing Cognitive Target in Phase II Alzheimer’s Trial
June 30, 2025
·
2 min read
·
Tristan Manalac
Influenza
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot
June 30, 2025
·
2 min read
·
Tristan Manalac
MASH
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
June 27, 2025
·
2 min read
·
Tristan Manalac
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
·
2 min read
·
Tristan Manalac